Heart Disease Trial, Recruiting NCT06659393 Sponsor: Novartis Pharmaceuticals Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT06659393
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • A parent or legally acceptable representative must provide written consent before treatment begins
  • Children aged 1 to under 18 years old who are starting Entresto for the first time to treat chronic heart failure

Who may not be able to join:

  • Children who have previously taken any medication containing the same active ingredients as Entresto, including in other clinical studies
  • Children who have had an allergic reaction to any ingredient in Entresto
  • Children who are currently taking, or have taken within the last 36 hours, a type of blood pressure medication called an ACE inhibitor (this includes medications such as enalapril, captopril, lisinopril, and several others — confirm with trial site for the full list)
  • Children who have a history of a condition called angioedema (severe swelling, sometimes caused by certain medications or inherited conditions)
  • Children with diabetes who are being treated with a medication called aliskiren fumarate, unless their blood pressure remains very poorly controlled despite other treatments
  • Children with severe liver disease (classified as Child-Pugh class C)
  • Anyone who is pregnant or may be pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +81337978748

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
19 December 2024
Est. completion
30 November 2027

Where this trial is recruiting

🇯🇵 Japan

Primary endpoints

Occurrence of events related to hypotension, hyperkalemia, renal impairment/renal failure, and dehydration

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov